NovoCure (NASDAQ:NVCR) Price Target Cut to $15.00 by Analysts at Wells Fargo & Company

NovoCure (NASDAQ:NVCR) had its price target decreased by Wells Fargo & Company from $20.00 to $15.00 in a research report report published on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical equipment provider’s stock.

A number of other brokerages have also recently issued reports on NVCR. HC Wainwright set a $32.00 target price on NovoCure in a report on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of NovoCure in a report on Thursday, August 27th. JPMorgan Chase & Co. assumed coverage on shares of NovoCure in a research note on Monday, July 13th. They issued a “neutral” rating and a $17.00 price objective on the stock. Wedbush lifted their price objective on shares of NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Finally, Wall Street Zen downgraded shares of NovoCure from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NovoCure currently has an average rating of “Hold” and an average price target of $20.80.

NovoCure Stock Up 0.3%

NVCR stock opened at $13.15 on Friday. The stock’s 50 day simple moving average is $15.79 and its 200 day simple moving average is $14.79. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $21.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89. The company has a market cap of $1.53 billion, a P/E ratio of -12.41 and a beta of 0.99.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.14. NovoCure had a negative return on equity of 36.18% and a negative net margin of 16.78%. The business had revenue of $193.40 million for the quarter, compared to analyst estimates of $182.28 million. During the same quarter in the prior year, the company earned ($0.33) earnings per share. The company’s quarterly revenue was up 15.7% on a year-over-year basis. On average, research analysts expect that NovoCure will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NovoCure

Several institutional investors have recently bought and sold shares of the stock. Quantinno Capital Management LP raised its holdings in shares of NovoCure by 23.7% in the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock valued at $27,112,000 after purchasing an additional 477,128 shares during the last quarter. Renaissance Technologies LLC increased its stake in NovoCure by 11.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,551,554 shares of the medical equipment provider’s stock valued at $16,912,000 after buying an additional 163,800 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in NovoCure by 27.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 960,056 shares of the medical equipment provider’s stock valued at $10,462,000 after buying an additional 207,913 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in NovoCure in the 2nd quarter valued at about $2,248,000. Finally, California State Teachers Retirement System lifted its position in shares of NovoCure by 43.6% during the 1st quarter. California State Teachers Retirement System now owns 142,561 shares of the medical equipment provider’s stock worth $1,554,000 after buying an additional 43,257 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

More NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. Its adjusted loss of $0.09 per share was substantially narrower than the expected $0.23 loss and the year-ago loss of $0.33. NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat
• Positive Sentiment: Management raised its 2026 guidance, reinforcing expectations for continued revenue growth and improved financial performance. The earnings call also provided additional detail on the company’s commercial and clinical strategy. NovoCure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
• Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 for pancreatic cancer. The partnership could expand the company’s pipeline and future indications. NovoCure and Verastem Collaboration
• Neutral Sentiment: Despite the earnings beat, NovoCure remains unprofitable, with a negative net margin and return on equity. Investors therefore remain focused on whether higher revenue and raised guidance can translate into sustainable profitability. NovoCure Third-Quarter Results
• Negative Sentiment: NovoCure’s CEO said adoption of the Optune Pax system was slowed by competition from Revolution Medicines’ daraxonrasib. Wedbush characterized the issue as a disruption rather than direct competition, but the slower adoption raises concerns about near-term commercial momentum. Optune Pax Adoption Commentary
• Negative Sentiment: Wells Fargo lowered its price target for NVCR from $20 to $15 and maintained an “equal weight” rating. Although the new target implies upside, the sharp reduction signals reduced confidence in the stock’s near-term risk-reward profile. Wells Fargo NovoCure Rating

About NovoCure

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.